...
首页> 外文期刊>Expert Review of Molecular Diagnostics >An update on microRNAs as colorectal cancer biomarkers: Where are we and what's next?
【24h】

An update on microRNAs as colorectal cancer biomarkers: Where are we and what's next?

机译:microRNA作为结直肠癌生物标志物的最新进展:我们在哪里,下一步是什么?

获取原文
获取原文并翻译 | 示例

摘要

miRNAs are abundant classes of small, endogenous non-coding RNAs, which inhibit the expression of target gene via post-transcriptional regulation. In addition to an important functional role miRNAs play in carcinogenesis, emerging evidence has demonstrated their feasibility as robust cancer biomarkers. In particular, the recent discovery of miRNAs in the body fluids provides an attractive opportunity for the development of non-invasive biomarkers for the diagnosis, prognosis and predictive response to cancer therapy. Colorectal cancer (CRC) is one of the most common cancers worldwide, and accumulating data provides a compelling case for the potential exploitation of miRNAs as CRC-biomarkers. This review summarizes the current state of literature in the field, focusing on the clinical relevance of miRNAs as potential biomarkers for CRC treatment and discussing the forthcoming challenges to further advance this exciting field of 'academic research' into 'bedside clinical care' of patients suffering from CRC.
机译:miRNA是一类丰富的小型内源性非编码RNA,它们通过转录后调控抑制靶基因的表达。除了miRNA在致癌作用中发挥重要的功能作用外,新的证据还证明了miRNA作为健壮的癌症生物标记物的可行性。特别地,体液中miRNA的最新发现为开发非侵入性生物标志物提供了诱人的机会,以用于诊断,预后和对癌症治疗的预测性反应。大肠癌(CRC)是全球最常见的癌症之一,积累的数据为miRNA作为CRC生物标志物的潜在利用提供了令人信服的案例。这篇综述总结了该领域的当前研究现状,着重于miRNA作为CRC治疗潜在生物标志物的临床相关性,并讨论了即将到来的挑战,以将这一令人兴奋的“学术研究”领域进一步推向患病患者的“床边临床护理”来自CRC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号